Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

September 16th, 2026

CDER, CBER Officials Outline GMP Compliance Trends

FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.

Global health safety regulation Concept, Businesswoman reviewing and approving FDA standard documents for medical and food, Compliance, laboratory inspection, certification, and international approval | Image credit: © Ticha - © Ticha - stock.adobe.com

September 16th, 2026

FDA, Sanofi, Gilead Weigh AI Readiness and Validation Risk at PDA/FDA Conference

Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.

Team of Research Scientists in Sterile Suits Working with Computers, Microscopes and Modern Industrial Machinery in the Laboratory. Product Manufacturing Process: Pharmaceutics, Biotechnology. | Image credit: © Gorodenkoff - © Gorodenkoff - stock.adobe.com

September 16th, 2026

FDA Highlights Aseptic Processing Pitfalls at PDA/FDA Conference

FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.

Closeup of female hand with IV drip infusion in treatment session at hospital, copy space | Image credit: © Seventyfour - © Seventyfour - stock.adobe.com

September 16th, 2026

Japan Approves Tanabe Pharma's Inebilizumab for Myasthenia Gravis

Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.

Blue medical pens for glp-1 semaglutide therapy on a white background for illustrating diabetes control and morbid obesity treatment. | Image credit: © Shutterly - © Shutterly - stock.adobe.com

September 15th, 2026

The Shift From Intravenous to Subcutaneous Biologics in 2026

Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.

September 15th, 2026

The BioPharm Brief: AI, T-Cell Engagers, and Longevity Research

Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.

Modern biopharma enterprises are restructuring their IT operating models to achieve agility, ensure compliance, and drive scientific innovation. Credit: Stock.Adobe.com/Michael Traitov.

September 15th, 2026

Architecting the Future: The Evolution of IT Landscape in the Biopharma Industry

As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.

Genetic research and Biotech science Concept. | Image credit: © jittawit21 - © jittawit21 - stock.adobe.com

September 15th, 2026

Insilico Launches AI-Driven Longevity Vaccines Research Program

Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.